Skip to main content
. Author manuscript; available in PMC: 2013 Dec 23.
Published in final edited form as: Int J Gynecol Cancer. 2011 Apr;21(3):10.1097/IGC.0b013e31820cc305. doi: 10.1097/IGC.0b013e31820cc305

Table 3.

The univariate overall survival

Variable N %Alive 3-Yr Survival Rate (95%CI) 5-Yr Survival Rate (95%CI) Hazard Ratio p-value
All 1411 92.90% 93.5%(91.5~95.1%) 87.4%(84.3~89.9%)

1988 Stage I (N=1307)
 IA 570 96.80% 97.7%(95.1~99%) 92.4%(86.8~95.7%) Ref. Level <0.001
 IB 593 90.70% 92.4%(89.1~94.7%) 87.3%(82.9~90.6%) 2.21(1.3~3.76)
 IC 144 87.50% 88.4%(78.8~93.9%) 75.7%(62.8~84.7%) 3.54(1.84~6.82)

2009 Stage I (N=1411)
 IA 1249 93.70% 94.5%(92.5~96%) 89.2%(86.1~91.7%) Ref. Level 0.001
 IB 162 87% 86.8%(77.7~92.4%) 75.1%(63.1~83.7%) 2.19(1.35~3.56)

For 1988 IIA cohort (N=40)*
 2009 IA 29 96.60% 93.3%(61.3~99%) 93.3%(61.3~99%)
 2009 IB 11 81.80% 66.7%(16~91.4%) 66.7%(16~91.4%)

For 1988 IIIA cohort (N=105)**
 2009 IA 57 91.20% 89.7%(64~97.4%) 75.3%(45.3~90.3%)
 2009 IB 7 85.70% 75%(12.8~96.1%) 75%(12.8~96.1%)
 2009>=II 41 82.90% 89.2%(73.6~95.8%) 74.4%(52~87.5%)
*

The results show if there is any heterogeneity among 1988 IIA cohort stratified by 2009 criteria

**

The results show if there is any heterogeneity among 1988 IIIA cohort stratified by 2009 criteria